ABLi Therapeutics Completes Collaboration Agreement with The Michael J. Fox Foundation to include Risvodetinib in Path to Prevention Platform Trial
ATLANTA and BOSTON, Jan. 27, 2026 (GLOBE NEWSWIRE) — ABLi Therapeutics (“ABLi”), a biotechnology company developing therapeutics to address diseases that are associated with activation of Abelson Tyrosine Kinases (c-Abl kinases), announces it has entered into a collaboration agreement with The Michael J. Fox Foundation for Parkinson's Research (MJFF) to include ABLi's lead candidate, risvodetinib, […]